New Therapies for Dedifferentiated Papillary Thyroid Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2015 Mar 20

PMID 25789503

Citations 26

Authors

Poupak Fallahi

Valeria Mazzi

Roberto Vita

Silvia Martina Ferrari

Gabriele Materazzi

David Galleri

Salvatore Benvenga

Paolo Miccoli

Alessandro Antonelli

Affiliations

Soon will be listed here.

Abstract

The number of thyroid cancers is increasing. Standard treatment usually includes primary surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid remnant with radioactive iodine (RAI). Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will develop metastatic disease, which fails to respond to RAI, exhibiting a more aggressive behavior. The lack of specific, effective and well-tolerated drugs, the scarcity of data about the association of multi-targeting drugs, and the limited role of radioiodine for dedifferentiated thyroid cancer, call for further efforts in the field of new drugs development. Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer. Targeted novel compounds have been demonstrated to induce clinical responses and stabilization of disease. Sorafenib has been approved for differentiated thyroid cancer refractory to RAI.

Citing Articles

Celastrol promotes apoptotic cell death in thyroid cancer cells through a caspases-dependent pathway.

Yang R, Yao J, Ma H, Shui C, Li T, Zhang S Thyroid Res. 2025; 18(1):9.

PMID: 40001245 PMC: 11863774. DOI: 10.1186/s13044-024-00222-7.

Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target.

Huo M, Adeerjiang Y, Abulitipu A, Khan U, Li X, Zhang L Front Oncol. 2024; 14:1325575.

PMID: 39534095 PMC: 11554530. DOI: 10.3389/fonc.2024.1325575.

Metabolic adverse events of multitarget kinase inhibitors: a systematic review.

Acitelli E, Maiorca C, Grani G, Maranghi M Endocrine. 2023; 81(1):16-29.

PMID: 37067769 PMC: 10239378. DOI: 10.1007/s12020-023-03362-2.

miR-576-5p Promotes the Proliferation of Papillary Thyroid Carcinoma through the MAPK4-AKT Pathway.

Hai R, Zhou Y, Li F, Guo Q, Long Y, Wang F Int J Anal Chem. 2023; 2022:1428411.

PMID: 36618768 PMC: 9815926. DOI: 10.1155/2022/1428411.

TREM2 Is a Prognostic Biomarker and Correlated with an Immunosuppressive Microenvironment in Thyroid Cancer.

Wang J, Li Z Dis Markers. 2022; 2022:1807386.

PMID: 36438899 PMC: 9683966. DOI: 10.1155/2022/1807386.

References

Diez J, Iglesias P, Alonso T, Grande E . Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice. Endocrine. 2014; 48(2):582-8. DOI: 10.1007/s12020-014-0356-1. View

Klein M, Picard E, Vignaud J, Marie B, Bresler L, Toussaint B . Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 1999; 161(1):41-9. DOI: 10.1677/joe.0.1610041. View

Pacini F . Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria. Thyroid. 2008; 18(3):279-80. DOI: 10.1089/thy.2008.0038. View

Fallahi P, Ferrari S, Vita R, Di Domenicantonio A, Corrado A, Benvenga S . Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf. 2014; 13(6):723-33. DOI: 10.1517/14740338.2014.913021. View

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B . Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol. 2011; 9(3):187-99. View

Kogai T, Brent G . The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012; 135(3):355-70. PMC: 3408573. DOI: 10.1016/j.pharmthera.2012.06.007. View

Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R . Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics. 2012; 12(8):609-17. PMC: 3271313. DOI: 10.2174/138920211798120853. View

Lamalice L, Le Boeuf F, Huot J . Endothelial cell migration during angiogenesis. Circ Res. 2007; 100(6):782-94. DOI: 10.1161/01.RES.0000259593.07661.1e. View

10.

Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C . Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid. 2003; 13(5):479-84. DOI: 10.1089/105072503322021142. View

11.

Fallahi P, Ferrari S, Mazzi V, Vita R, Benvenga S, Antonelli A . Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014; 15(3):190-202. PMC: 4064559. DOI: 10.2174/1389202915999140404101902. View

12.

Patson B, Cohen R, Olszanski A . Pharmacokinetic evaluation of axitinib. Expert Opin Drug Metab Toxicol. 2012; 8(2):259-70. DOI: 10.1517/17425255.2012.652947. View

13.

Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari S, Mancusi C . CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2014; 99(4):E572-81. DOI: 10.1210/jc.2013-2321. View

14.

Ye L, Santarpia L, Gagel R . The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 2010; 31(4):578-99. DOI: 10.1210/er.2009-0031. View

15.

Luong Q, OKelly J, Braunstein G, Hershman J, Koeffler H . Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006; 12(18):5570-7. DOI: 10.1158/1078-0432.CCR-06-0367. View

16.

Faggiano A, Ramundo V, Dicitore A, Castiglioni S, Borghi M, Severino R . Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med. 2011; 16(7):1563-72. PMC: 3823224. DOI: 10.1111/j.1582-4934.2011.01438.x. View

17.

Souza E, Padron A, Braga W, de Andrade B, Vaisman M, Nasciutti L . MTOR downregulates iodide uptake in thyrocytes. J Endocrinol. 2010; 206(1):113-20. DOI: 10.1677/JOE-09-0436. View

18.

Strumberg D, Clark J, Awada A, Moore M, Richly H, Hendlisz A . Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007; 12(4):426-37. DOI: 10.1634/theoncologist.12-4-426. View

19.

Bravo S, Garcia-Rendueles M, Seoane R, Dosil V, Cameselle-Teijeiro J, Lopez-Lazaro L . Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. Clin Cancer Res. 2005; 11(21):7664-73. DOI: 10.1158/1078-0432.CCR-05-0455. View

20.

Karwowski J, Nowels K, McDougall I, Weigel R . Needle track seeding of papillary thyroid carcinoma from fine needle aspiration biopsy. A case report. Acta Cytol. 2002; 46(3):591-5. DOI: 10.1159/000326884. View